<DOC>
	<DOC>NCT00740116</DOC>
	<brief_summary>The purpose of the study is to determine if a standardized single dose tranexamic acid given intravenously immediately preoperatively reduces the perioperative bleeding volume and reduces the need of blood transfusion in women undergoing surgery for advanced ovarian cancer.</brief_summary>
	<brief_title>Tranexamic Acid in Surgery of Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Females ages 18 or older with a pelvic or abdominal tumor suspected or histopathologically proven ovarian cancer FIGO stage IIIV who are undergoing primary surgery with the intention of performing optimal cytoreductive radical surgery. Understand and speak Swedish Accept participation in the study after written and verbal information and sign informed consent. Allergy to tranexamic acid Having had tranexamic acid within the recent 30 days Previous or present episode of thromboembolic events . Previous or present treatment within the recent 3 months with anticoagulant. Previous or present known coagulopathy Myocardial infarction within the previous 12 months or instable angina pectoris which, according to the investigator, may increase the risk for complications significantly in case of a lowering of the hemoglobin. Significant renal failure with serumcreatinine &gt; 250 Âµmol/l. Severe psychiatric dysfunction or mentally substantially disabled.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Tumor of ovary</keyword>
	<keyword>Surgical blood loss</keyword>
	<keyword>Postoperative blood loss</keyword>
	<keyword>Preventive therapy</keyword>
	<keyword>Thromboembolism</keyword>
</DOC>